Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 76Terminated 15Unknown 13Recruiting 8Withdrawn 2Suspended 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 13Neoplasms 12Neoplasm Metastasis 9Melanoma 7Prostatic Neoplasms 6Ovarian Neoplasms 6Myelodysplastic Syndromes 6Breast Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Glioma 5Colorectal Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Glioblastoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumors 2Solid Tumor 2Sarcoma 2Osteosarcoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2

Interventions

Ifosfamide 1Amblyomin-X protein, Amblyomma cajennense 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Advanced Cancer × Clear all
NCT03120130 2019-10-14

Amblyomin-X

União Química Farmacêutica Nacional S/A

Phase 1 Suspended
24 enrolled

Advanced Cancer

NCT00607711 2008-05-05

Study of Oral Palifosfamide Tris in Solid Tumors

Alaunos Therapeutics

Phase 1 Suspended
20 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡